Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 4/20 | 0.67 |
| ▸ | RAD1 | O60671 | 1/20 | 0.58 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.58 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | LTA | P01374 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acridine SCHEMBL6290391 | 1.00 | RAD51 (0.67) | RAD51RAD1P2RY6ENPP2APEX1 | |
| Acridine SCHEMBL3232431 | 0.97 | RAD51 (0.64) | RAD51RAD1P2RY6ENPP2APEX1 | |
| SCHEMBL29351606 | 0.90 | RAD51 (0.81) | RAD51RAD1P2RY6ENPP2APEX1 | |
| SCHEMBL25796 | 0.90 | RAD51 (0.81) | RAD51RAD1P2RY6ENPP2APEX1 | |
| SCHEMBL175934 | 0.90 | RAD51 (0.81) | RAD51RAD1P2RY6ENPP2APEX1 | |
| SCHEMBL2333703 | 0.89 | RAD51 (0.80) | RAD51RAD1P2RY6ENPP2APEX1 | |
| SCHEMBL15823509 | 0.89 | RAD51 (0.80) | RAD51RAD1P2RY6ENPP2APEX1 | |
| SCHEMBL30160852 | 0.89 | RAD51 (0.80) | RAD51RAD1P2RY6ENPP2APEX1 | |
| SCHEMBL2333711 | 0.89 | RAD51 (0.80) | RAD51RAD1P2RY6ENPP2APEX1 | |
| Acridine SCHEMBL5792145 | 0.87 | RAD1 (0.53) | RAD51RAD1P2RY6ENPP2APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427854-A1 | METHODS FOR QUANTIFYING NUCLEAR RUN-ON TRANSCRIPTIONAL ASSAYS | Benitec Australia Ltd. (AU) | 2004-06-16 | — | — | EP | claimed |
| WO-2003018832-A1 | METHODS FOR QUANTIFYING NUCLEAR RUN-ON TRANSCRIPTIONAL ASSAYS | BENITEC AUSTRALIA LTD (AU) | 2003-03-06 | — | — | WO | claimed |
| WO-2023096721-A1 | FRET-ACTIVE E2-UBL CONJUGATES AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-4058580-A1 | ENGINEERED GYRI-LIKE MUTEIN APTAMERS, AND RELATED METHODS | Crosslife Technologies Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021263188-A9 | LIVE CELL ENGAGEMENT ASSAY | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2021263188-A1 | LIVE CELL ENGAGEMENT ASSAY | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021096759-A1 | ENGINEERED GYRI-LIKE MUTEIN APTAMERS, AND RELATED METHODS | CROSSLIFE TECHNOLOGIES INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210139958-A1 | ENGINEERED GYRI-LIKE MUTEIN APTAMERS, AND RELATED METHODS | CROSSLIFE TECHNOLOGIES INC. | 2021-05-13 | — | — | US | disclosed |
| US-20200384126-A1 | DETECTION OF HIGH RISK DRUSEN | SIXTH STREET LENDING PARTNERS | 2020-12-10 | — | — | US | disclosed |
| EP-3268743-B1 | COMBINATION TREPONEMAL AND NON-TREPONEMAL SYPHILIS TEST | BIO RAD LABORATORIES (US) | 2020-09-02 | — | — | EP | disclosed |
| US-10648981-B2 | Combination treponemal and non-treponemal syphilis test | BIO-RAD LABORATORIES, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-1250451-A1 | OLIGONUCLEOTIDES AND ASSEMBLIES THEREOF USEFUL IN THE DETECTION OF THE PRESENCE OR ABSENCE OF TARGET NUCLEIC ACID SEQUENCES IN A SAMPLE | GAMIDA SENSE DIAGNOSTICS LTD. (IL) | 2002-10-23 | — | — | EP | disclosed |
| WO-2002057479-A2 | PRIMERS AND METHODS FOR THE DETECTION AND DISCRIMINATION OF NUCLEIC ACIDS | INVITROGEN CORPORATION (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2000079009-A9 | IMPROVED PRIMERS AND METHODS FOR THE DETECTION AND DISCRIMINATION OF NUCLEIC ACIDS | INVITROGEN CORP (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002044399-A2 | IN VITRO TRANSCRIPTION METHOD FOR RNA AMPLIFICATION | ROSETTA INPHARMATICS, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| EP-1190097-A2 | IMPROVED PRIMERS AND METHODS FOR THE DETECTION AND DISCRIMINATION OF NUCLEIC ACIDS | INVITROGEN CORPORATION (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001086001-A1 | DARK QUENCHERS FOR DONOR-ACCEPTOR ENERGY TRANSFER | BIOSEARCH TECHNOLOGIES, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
| US-6271002-B1 | A POLYMERASE CHAIN REACTION KIT FOR INCORPORATING AN RNA POLYMERASE PROMOTER INTO DOUBLE STRANDED CDNA BY AMPLIFICATION WITH AN RNA PRIMER FOR LESS THAN 20 CYCLES; THEN THE RNA POLYMERASE CONTAINING CDNA IS THEN TRANSCRIBED INTO RNA | ROSETTA INPHARMATICS, INC. | 2001-08-07 | — | — | US | disclosed |
| WO-2001038570-A1 | OLIGONUCLEOTIDES AND ASSEMBLIES THEREOF USEFUL IN THE DETECTION OF THE PRESENCE OR ABSENCE OF TARGET NUCLEIC ACID SEQUENCES IN A SAMPLE | GAMIDA SENSE DIAGNOSTICS LTD. (IL) | 2001-05-31 | — | — | WO | disclosed |
| WO-2000079009-A2 | IMPROVED PRIMERS AND METHODS FOR THE DETECTION AND DISCRIMINATION OF NUCLEIC ACIDS | INVITROGEN CORPORATION (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200384126-A1 | DETECTION OF HIGH RISK DRUSEN | IL17A, EXOSC4, CFB | RAD51 1352/4885RAD1 3003/4885P2RY6 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.